Biocon Limited — Important, 18-02-2025: Updates

Biocon Biologics Ltd has received marketing authorization from the European Commission for YESINTEK®, a biosimilar of Ustekinumab. This biosimilar is indicated for the treatment of plaque psoriasis in adults and children, as well as for adults with psoriatic arthritis or Crohn's disease. Clinical trial data demonstrated that YESINTEK® offers comparable safety and efficacy to the original Ustekinumab product. The approval follows a favorable opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use in December 2024. This development enhances Biocon's portfolio in the biosimilars market and opens up new revenue avenues in key therapeutic areas. Watch closely as this approval may significantly impact growth potential in the European market.